XML 49 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Business Acquisitions and Divestitures - Acquisitions (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Nov. 01, 2022
Oct. 31, 2022
Sep. 30, 2023
Sep. 30, 2023
Mar. 31, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Fair value adjustment gain     $ 48 $ 76  
Goodwill     9,934 9,934 $ 9,947
U.S. Pharmaceutical          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Goodwill     4,043 4,043 4,050
Rx Savings Solutions, LLC | RxTs Segment          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Business acquisition, percentage of controlling interest in combined business 100.00%        
Cash payments to acquire business $ 600        
Contingent consideration 92        
Other current liabilities     15 15 83
Other non-current liabilities     $ 1 $ 1 $ 9
Acquired identifiable intangible assets $ 229        
Weighted average life of intangibles 12 years        
Goodwill $ 463        
Rx Savings Solutions, LLC | RxTs Segment | Maximum          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Contingent consideration $ 275        
SCRI Oncology, LLC | U.S. Pharmaceutical          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Business acquisition, percentage of controlling interest in combined business   51.00%      
Cash payments to acquire business   $ 166      
Acquired identifiable intangible assets   $ 177      
Weighted average life of intangibles   17 years      
Goodwill   $ 113      
Goodwill, expected tax deductible amount   46      
Noncontrolling interest   222      
SCRI Oncology, LLC | U.S. Pharmaceutical | SCRI          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Noncontrolling interest   202      
SCRI Oncology, LLC | U.S. Pharmaceutical | USOR          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Noncontrolling interest   $ 20